Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ER-Negative PR-Negative HER2-Negative Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)UnknownNCT02595138
What this trial is testing

Zoledronic Acid as Adjuvant Treatment of Triple-negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
Chinese Academy of Medical Sciences 430
Testing effectiveness (Phase 2)UnknownNCT04913571
What this trial is testing

Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer：A Prospective Multiple-center Phase II Study

Who this might be right for
Triple Negative Breast Cancer
Fudan University 265
Testing effectiveness (Phase 2)UnknownNCT02511847
What this trial is testing

Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of Afatinib

Who this might be right for
Triple Negative Breast Cancer
National Taiwan University Hospital 40
Early research (Phase 1)Looking for participantsNCT07503808
What this trial is testing

IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

Who this might be right for
Esophageal Squamous Cell CarcinomaHigh Grade Serous Ovarian CancerHead and Neck Squamous Cell Carcinoma+5 more
IDEAYA Biosciences 150
Testing effectiveness (Phase 2)WithdrawnNCT05234606
What this trial is testing

A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors

Who this might be right for
Urothelial CarcinomaTriple Negative Breast CancerNon-small Cell Lung Cancer+2 more
Silverback Therapeutics
Testing effectiveness (Phase 2)Study completedNCT01618136
What this trial is testing

An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors

Who this might be right for
Malignant Solid TumourOvarian CancerTriple Negative Breast Cancer+2 more
Eisai Limited 41
Testing effectiveness (Phase 2)Study completedNCT00633464
What this trial is testing

Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer

Who this might be right for
Triple Negative Locally Advanced Non-resectable Breast CancerMetastatic Breast Cancer
R-Pharm 79
Not applicableEnrolling By InvitationNCT06885424
What this trial is testing

A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products

Who this might be right for
Solid Tumor CancerSolid Tumor, Unspecified, AdultColorectal Carcinoma+12 more
A2 Biotherapeutics Inc. 400
Early research (Phase 1)WithdrawnNCT01333423
What this trial is testing

Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)

Who this might be right for
Breast Cancer
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Looking for participantsNCT06768931
What this trial is testing

Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer

Who this might be right for
Breast CancerTriple Negative Breast Cancer (TNBC)Early Stage Breast Cancer+2 more
Sun Yat-sen University 192
Early research (Phase 1)Study completedNCT04148937
What this trial is testing

The CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer

Who this might be right for
Advanced Cancer
Eli Lilly and Company 52
Early research (Phase 1)Ended earlyNCT02419495
What this trial is testing

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

Who this might be right for
Advanced Malignant Solid NeoplasmClinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8+26 more
M.D. Anderson Cancer Center 221
Early research (Phase 1)UnknownNCT05692661
What this trial is testing

A Dose Escalation Study of Proton and Carbon Ion Irradiation for HER2 Positive and Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast CancerHER2-positive Breast Cancer
Shanghai Proton and Heavy Ion Center 24
Testing effectiveness (Phase 2)Study completedNCT03304756
What this trial is testing

Study of Neoadjuvant Treatment of Locally Advanced Breast Cancer With CAP Regimen

Who this might be right for
Triple Negative Breast Cancer Patients
Instituto Nacional de Cancer, Brazil 41
Testing effectiveness (Phase 2)Looking for participantsNCT06471205
What this trial is testing

BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer

Who this might be right for
Triple-negative Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 52
Testing effectiveness (Phase 2)Ended earlyNCT04216472
What this trial is testing

Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations

Who this might be right for
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8+19 more
M.D. Anderson Cancer Center 6
Testing effectiveness (Phase 2)Ended earlyNCT04424641
What this trial is testing

A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors

Who this might be right for
Locally Advanced or Metastatic Solid Tumor(s)Prostate CancerEsophageal Cancer+5 more
Genmab 48
Testing effectiveness (Phase 2)Study completedNCT03872791
What this trial is testing

KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast Cancer

Who this might be right for
Triple-negative Breast Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd 52
Testing effectiveness (Phase 2)Study completedNCT00733408
What this trial is testing

Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor-negative Breast CancerHER2-negative Breast CancerProgesterone Receptor-negative Breast Cancer+3 more
University of Washington 59
Testing effectiveness (Phase 2)Study completedNCT03358017
What this trial is testing

Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
Mario Negri Institute for Pharmacological Research 54
Next Page